Latest
progress
Salubris,
recently announced the completion of enrollment in the Phase 3 clinical trial study
of S086 in patients with hypertension.
S086 is
an angiotensin II receptor- Neprilysin dual inhibitor with targeted indications
for hypertension and chronic heart failure (HFrEF). S086 is the second
ARNi-type small molecule in the world to enter the clinic trial study. In
December 2021, the first patient in this Phase III clinical trial for mild to
moderate primary hypertension was enrolled. After eight months, the enrollment
was successfully completed.
The
clinical trial of S086 tablet has made positive progress. When the product is
launched, it will benefit more hypertensive patients and help Salubris maintain
high-quality development in the cardiovascular area.
Clinical
trial related
This
trial is a randomized, double-blind, active drug parallel-controlled,
multi-center phase 3 clinical study, of which the PI (principal investigator)
is Professor Wang Jiguang from Ruijin Hospital Affiliated to Shanghai Jiaotong
University School of Medicine. This trial is designed to evaluate the safety
and efficacy of different doses of S086 in patients with mild to moderate
primary hypertension.
